Background: Idiopathic Juvenile Osteoporosis (IJO) refers to significantly lower than expected bone mass manifesting in childhood with no identifiable aetiology. IJO classically presents in early pubertal period with multiple fractures including metaphyseal and vertebral crush fractures, and low bone-mass.
| I N TR ODU C TI ON
Idiopathic juvenile osteoporosis (IJO) is the descriptive term used to define primary osteoporosis of unknown etiology presenting in childhood. It is usually associated with vertebral and metaphyseal fractures in the years leading to puberty. It has been previously reported to not be associated with heritable genetic variants and usually diagnosed by a process of elimination through exclusion of other causes of decreased bone density . The classic pathophysiology of IJO involves a dysfunction in cancellous bone formation in two ways: fewer remodeling cycles and reduction in quantity of bone formed in each of these cycles. This leads to thin trabeculae by the time of maturity . Hartikka et al. (2005) reported heterozygous variants in LRP5 in a small number of children with IJO more than a decade ago. Genetic causes of osteoporosis have now been increasingly identified due to advances in genetic screening, with variants in genes with dominant, recessive and X-linked recessive inheritance patterns (Biha et al., 2016; Fahiminiya et al., 2014; Kampe et al., 2015; Rocha-Braz and Ferraz-deSouza, 2016) .
PLS3 (OMIM 300131) has 16 exons and is located on Xq23, it encodes a highly conserved plastin 3 that binds actin and shown to have an effect on bone mineral density. Plastin 3 is ubiquitously expressed in solid tissues and involved in the binding and bundling of actin filaments in the cytoskeleton. Variants in PLS3 lead to significantly reduced bone mineral density (Laarschot et al., 2016; Laine et al., 2015; McGovern et al., 2015) . Although, the exact function of PLS3 in bone is still unknown, suggested roles of Plastin 3 includes the processes of mechanosensing, converting applied mechanical loading forces into molecular signals that are interpreted by the cells. More recently, it has been suggested to have a role in the mineralization process. Being located on the X chromosome, PLS3-induced osteoporosis has a more severe effect on males than females, although heterozygous carrier females are also known have early-onset osteoporosis.
Here, we report two patients initially diagnosed clinically as IJO in whom PLS3 pathogenic variants were identified. Although there have been several large pedigrees reported with plastin-induced osteoporosis in the literature, bone material properties have not been extensively studied and results have been varied. In the current report, we demonstrate this variability further and attempt genotype-phenotype correlation in order to untangle the results on detailed bone material analyses.
| M A TE RI A L S A ND M E TH ODS

| Clinical report
Patient 1: The first patient is a 40-year-old Caucasian male who initially presented to a Pediatric Metabolic Bone service outside of our center at the age of 12 years, with a history of musculoskeletal aches and pains and morning stiffness.
On examination at that time, he was noted to be short in the trunk, and showed difficulty moving from a position of forward flexion to an upright position. X-rays were reported as showing generalized osteopenia with compression of almost all lower thoracic and lumbar vertebrae, consistent with a clinical diagnosis of "Osteoporosis" or "Osteogenesis Imperfecta." He had an elevated alkaline phosphatase, but no other abnormality was noted on investigation. He was given a diagnosis of IJO at age 13. He was instructed to wear a supportive back brace but received no specific therapy. It is of note that his mother, then in her 40s, had already been diagnosed with osteoporosis ( Figure 1a) . He was subsequently lost to follow-up.
Aged 38, this patient was referred to the adult metabolic bone service, following a fracture of his hip, which occurred during an accident at work. Additionally, he gave a history of a traumatic foot fracture. On examination, he had white sclerae, was not facially dysmorphic with no other features suggestive of OI or other metabolic bone disease. During diagnostic work-up, he was noted to have multiple vertebral fractures and recalled the history of IJO. Investigations did not identify any other contributory causes. His bone density was below the expected range for age; lumbar spine T-score was 24.8
(although the presence of vertebral fractures affects the reliability of the result), Z-score was 24.8, total hip T-score was 23.5 with a Z-score of 23.6. Spinal imaging demonstrated fractures of all lumbar vertebrae and most of the thoracic vertebrae (with the exception of T3) (Figure 1b and c Eight months after starting treatment, his lateral vertebral analysis showed six vertebrae with reduced height; his age-matched lumbar spine aBMD Z-score had risen from 22.7 prior to treatment to 21.4 and his total body less head aBMD Z-score rose from 22.6 to 21.7. He was referred to the Genetics clinic in view of his bone fragility and a diagnosis of autism spectrum disorder (ASD). A detailed family pedigree was taken which confirmed that his mother had sustained a fracture of her forearm but there was a more significant fracture history in a maternal aunt who had been diagnosed with osteoporosis in her 30s. He was enrolled to a research study looking at the association of bone fragility and autism with appropriate consent and trio whole exome sequencing was undertaken.
| Bone histomorphometry and quantitative backscattered electron imaging
A transiliac bone biopsy was obtained from Patient 2 before the initiation of bisphosphonate (BP) treatment, following double labeling with tetracycline to allow for dynamic measurement of bone formation. Sample preparation and histomorphometric analyses were performed using standard procedures . Results were compared to reference data of healthy age-matched controls and children with OI type I . Subsequently, the residual block was prepared to assess bone mineralization density distribution (BMDD), reflecting the calcium content of cortical and trabecular bone matrix, by The qualitative assessment of the bone biopsy sample obtained from the patient prior initiation of bisphosphonate therapy revealed very small and isolated trabecular features; one very trabecularised cortex and one well-delineated cortical plate (see Figure 3a) . Under polarized light, cortical and trabecular bone showed an ordered lamellar pattern. In particular, the parallel lamellar organization of the cortical plates suggested that they were formed by primary bone apposition through processes of bone modeling and modeling drift (Figure 3b ).
The bone histomorphometric analyses confirmed that the amount of trabecular (bone volume per tissue volume) was severely reduced compared to aged-matched controls and rather in the range of OI patients (see Table 1 ). However, in contrast to OI bone, all parameters of bone formation and bone resorption were also found to be very low. Compared to healthy control values, osteoid thickness, mineral apposition rate and the mineralizing surface were decreased. The percentage of trabecular surfaces covered either by osteoblasts or osteoclasts was reduced by about 80% and 90%, respectively (Figure 3c ). It should be noted that more osteoclasts and osteoblasts were viewed in the cortical areas (not shown) mirroring an active trabecularization process.
The qBEI analyses revealed a hypermineralization of the bone matrix similar as in OI bone. In both the trabecular and cortical compartment, the BMDD curve was shifted towards a higher mineral content compared to healthy controls (Figure 3d, e) . Consistently, the average calcium content of the matrix (CaMean), the most frequently occurring calcium concentration (CaPeak) and the portion of highly mineralized bone (CaHigh) were elevated in both bone compartments, while the percentage of lowly mineralized matrix (CaLow) was markedly reduced (see Table 2 ).
| D ISC USSION
Osteoporosis is a complicated diagnosis to make, due to the range of factors that can contribute to its pathogenesis. It is characterized by reduced bone mass and an increased predisposition for bone fractures.
Current definition of childhood-onset primary osteoporosis requires a clinically significant fracture history and BMD Z-score at or below 22.0 (Kämpe et al., 2015) . A clinically significant fracture history can be defined as two or more long bone fractures aged 10 years or below and three or more long bone fractures aged 19 years or below. The bone regulatory actions of PLS3 are not fully known. It has been demonstrated that overexpression protects against spinal muscular atrophy. It has also been observed in zebrafish that knockout pls3 fish develop craniofacial bone structure malformations, which was reversible using human PLS3 mRNA (McGovern et al., 2015) . Dijk et al. (2013) observed that the chicken homolog for PLS3 (fimbrin) is highly expressed in osteocyte dendrites responsible for mechanosensation (Dijk et al., 2013) . The authors propose loss of mechanosensation as a possible mechanism for the osteoporosis effects.
Whilst the particular variants exhibited by both these patients in this study have not been published elsewhere, other frameshift variants in this gene have been found to cause X-linked osteoporosis. Maternal heterozygotes have been shown to be either unaffected or show early osteoporosis symptoms, as was the case with these patients (OI variant database: Dalgleish, 2017) .
Since its first description of PLS3-osteoporosis in five families with apparent X-linked osteoporosis, there have been other case reports adding to the literature and expanding the phenotype of this condition (Dijk et al., 2013; Laarschot et al., 2016; Kannu et al., 2017; Lv et al., 2017; Kämpe et al., 2017) . From the literature so far and corroborated by our patients, the phenotype consists of vertebral compression fractures, peripheral including long bone fractures and low BMD but without features such as blue sclerae, short stature, joint hyperlaxity, or facial features typical of "Classical OI" which is helpful in terms of genotype-phenotype correlation. Therefore, in patients with predominant history of vertebral fractures and/or low BMD without features of OI and family history suggestive of X-linked osteoporosis, PLS3-osteoporosis remains the top differential diagnosis. It is also important to make this diagnosis as carrier females albeit more mildly affected than males must be screened and kept under appropriate follow-up.
Patient 2 had features of ASD in addition to bone fragility and was recruited to a research study to explore this association further. Exome data have not identified any other variants of interest apart from the PLS3 variant which is X-linked. So far, PLS3 patients have been reported to have normal intellectual development. Interestingly, reports of PLS3-osteoporosis patients include those pediatric patients labeled as having "spastic cerebral palsy," "waddling gait" and there has been a suggestion that PLS3 is linked to spinal muscular atrophy (SMA) (Hosseinibarkooie at al., 2017) . It is therefore, important to assess neuromuscular function and CNS assessment in further detail in these patients. Plastin 3 is said to be a protective modifier in SMA and reported to have a role in neuromuscular synapse maintenance which adds further weight to the suggestion that in addition to the role in bone mineralization, this plastin may also have a role in intellectual development. It remains to be seen whether he has an alternate diagnosis to explain the ASD or the PLS3 variant is somehow contributing to his diagnosis of ASD. Further trio genome sequencing studies are ongoing to search for an alternate etiology. . c Thickness was only evaluated in the one well-delineated cortical plate.
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The extensive evaluation of the transiliac biopsy sample of Patient 2 revealed a novel bone phenotype associated with PLS3 variant.
Fahiminiya et al. (2014) first reported pediatric patients with normal
bone formation and normal BMDD (Fahiminiya et al., 2014) . In a more recent study from Kämpe et al. (2017) , data from a PLS3 variant carrier were presented that showed increased osteoid formation and concomitant hypomineralization of the bone matrix (Kämpe et al., 2017) . In sharp contrast, Patient 2 of the present study had low bone turnover, low osteoid formation compared to healthy controls and very low values compared to OI as shown in Table 1 . Indeed, children with OI tend to have elevated indices of bone formation and resorption that was definitively not observed in the present case . However, this PLS3 patient shares with OI patients, the characteristic decreased trabecular bone volume and the abnormally high mineral content of the bone matrix as revealed by qBEI (Table 2 ) . This suggests that the increased matrix mineralization in our PLS3 patient (Patient 2) results primarily from a long history of very low bone turnover.
Indeed, the mineralization of bone tissue increases with time and it takes years for a newly formed bone packet to become fully mineralized. Thus, in a situation where little or no bone is remodeled, one would expect a rising of the mineral content of the bone matrix and high bone matrix mineralization making the bone tissue stiffer, harder and more brittle Bishop 2016) . It has to be underlined that during skeletal growth, bone turnover is generally increased and the bone matrix tends to be rather lower mineralized than hypermineralized (Fratzl-Zelman et al., 2009) with several affected males identifying another X-linked gene resulting in heritable bone fragility (Lindert et al., 2016) . The phenotype of these patients was not in keeping with the diagnosis of IJO and was suggestive of a severe OI phenotype. In addition to the implicit benefit of screening for PLS3, the literature suggests that it would also be beneficial to screen LRP5/6 and WNT1 in patients with a presumed diagnosis of IJO. The proteins encoded by these genes form part of a major bone anabolic pathway; variants in genes for other factors interacting with the pathway including WNT3a, DKK1, and LRP4 have all also been associated with low bone mass and fracture. Variations in LRP5 can Note. Reference data are given as mean 6 SD or median with interquartile range (25%; 75%). Definition of BMDD variables from . CaMean: the mean calcium concentration (weighted mean); CaPeak: the most frequently occurring calcium concentration (the peak position of the BMDD) in the sample; CaWidth: the width of the BMDD distribution (full width at half maximum) reflecting the heterogeneity in matrix mineralization; CaLow: the percentage of low mineralized bone area, which is mineralized below 17.68 wt.% calcium, normally reflecting bone areas undergoing primary mineralization; cause opposing effects on the bone density of the patient; a loss-offunction variant causes osteoporosis-pseudoglioma (OPPG) (Biha et al., 2016; Hartikka et al., 2005; Palsgaard et al., 2016) , whereas a gain-offunction variant can cause dramatic increases in bone density (Niziolek et al., 2015) . Confirming the genetic etiology in IJO/childhood-onset primary osteoporosis is important due to implications for patients' diagnosis and treatment; for the wider family in terms of cascade screening especially in a X-linked condition, providing accurate information on recurrence risk (as in Patient 1 where there is no risk for his unaffected sons which is reassuring for the family).
In conclusion, IJO/childhood-onset primary osteoporosis can be a complicated diagnosis, resulting from early onset bone fragility. We recommend that all young male patients with this prospective diagnosis undergo diagnostic analysis of PLS3, either as part of targeted gene panel testing for bone fragility or a single gene testing where there is reduced access to genomic sequencing technologies. Given the emerging phenotype of PLS3-osteoporosis, further case reports of this nature are important to expand on the spectrum of clinical presentation and add to the PLS3 mutation database.
